Skip to content

Core Laboratories CLB Weighted Average Number Of Assuming Diluted Shares Outstanding

Weighted Average Number Of Assuming Diluted Shares Outstanding at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
179.8M+6.3%
Evommune
 logo
Evommune EVMN
85.1M+1,171%
Evommune
 logo
Evommune EVMN
85.1M+1,171%
Frequency Electronics logo
Frequency ElectronicsFEIM
9.8M+1.7%
Belden logo
BeldenBDC
38.8M-3.4%
Popular logo
PopularBPOP
64.8M-6.4%

Other financials

Income statement

See full
Revenue$121.8M-1.4%
Operating income$1.9M-57.3%
Net income-$789.0K-412%
EPS (diluted)-$0.02

Balance sheet

See full
Cash & equivalents$22.8M+3.2%
Total debt$167.8M-6.8%
Total equity$268.9M+6.1%
Total assets$587.7M+0.3%

Cash flow

See full
Operating cash flow$4.0M-40.5%
CapEx$3.4M+23.8%
Free cash flow$517.0K-86.7%

Valuation

See full
Market cap$503.38M-13.5%
Enterprise value$648.4M-12.3%
P/E17.3×-3.4×
P/S-0.2×

Profitability

See full
Operating margin10.3%-0.2pp
Net margin5.5%+0.1pp
FCF margin4.3%-4.6pp

Returns & leverage

See full
Return on equity11.1%-0.4pp
Debt / equity0.6×-0.1×
Current ratio-0.2×

Where this comes from

Reported directly by Core Laboratories in its filing.

Tagged under the XBRL concept clb:WeightedAverageNumberOfAssumingDilutedSharesOutstanding.

The official record: Core Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Core Laboratories's weighted average number of assuming diluted shares outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Core Laboratories's weighted average number of assuming diluted shares outstanding?
Core Laboratories (CLB) reported weighted average number of assuming diluted shares outstanding of 46.1M in Q1 2026.
How has Core Laboratories's weighted average number of assuming diluted shares outstanding changed year-over-year?
Core Laboratories's weighted average number of assuming diluted shares outstanding decreased by 1.5% year-over-year, from 46.8M to 46.1M.
What is the long-term trend for Core Laboratories's weighted average number of assuming diluted shares outstanding?
Over 2 years (2023 to 2025), Core Laboratories's weighted average number of assuming diluted shares outstanding has grown at a -0.5% compound annual growth rate (CAGR), from 190.1M to 188.2M.
What does weighted average number of assuming diluted shares outstanding mean?
This metric represents the average number of common shares outstanding during the reporting period, adjusted to include the potential dilutive impact of all convertible securities, stock options, and other equity-based instruments. It provides a conservative view of the company's equity base by accounting for all potential future share issuances. Investors use this figure to calculate diluted earnings per share, which offers a more accurate reflection of profitability on a per-share basis.